thiamazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1745	60-56-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: methimazole methylimidazolethiol thyrozol thymidazole thymidazol thycapzol thiamazole tapazole methymazol	A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. Molecular weight: 114.17 Formula: C4H6N2S CLOGP: -0.34 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 15.27 ALOGS: -1 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

methimazole
methylimidazolethiol
thyrozol
thymidazole
thymidazol
thycapzol
thiamazole
tapazole
methymazol

A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.

Molecular weight: 114.17
Formula: C4H6N2S
CLOGP: -0.34
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 15.27
ALOGS: -1
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	8.76 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	93 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.86 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 21, 1950	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Agranulocytosis	324.90	14.11	124	8000	21297	50575703
Thyrotoxic crisis	221.69	14.11	45	8079	707	50596293
Hyperthyroidism	200.83	14.11	75	8049	12100	50584900
Antithyroid arthritis syndrome	66.33	14.11	9	8115	4	50596996
Hypothyroidism	66.16	14.11	50	8074	34075	50562925
Choanal atresia	59.11	14.11	9	8115	20	50596980
Exophthalmos	45.64	14.11	14	8110	1236	50595764
Blood thyroid stimulating hormone decreased	35.46	14.11	16	8108	4156	50592844
Drug-induced liver injury	35.26	14.11	32	8092	28063	50568937
Neutropenia	34.00	14.11	74	8050	147891	50449109
Dysmorphism	30.85	14.11	12	8112	2155	50594845
Anti-neutrophil cytoplasmic antibody positive vasculitis	30.04	14.11	12	8112	2310	50594690
Goitre	28.85	14.11	15	8109	5305	50591695
Pulmonary alveolar haemorrhage	26.67	14.11	13	8111	4014	50592986
Cardiac arrest	26.64	14.11	48	8076	83603	50513397
Mucocutaneous candidiasis	26.56	14.11	4	8120	8	50596992
Endocrine ophthalmopathy	26.39	14.11	7	8117	366	50596634
Polyarthritis	25.79	14.11	16	8108	7911	50589089
Oropharyngeal pain	25.23	14.11	45	8079	77756	50519244
Aplasia cutis congenita	25.23	14.11	5	8119	69	50596931
Neuroglycopenia	25.23	14.11	5	8119	69	50596931
Thyroxine free increased	25.18	14.11	8	8116	793	50596207
Drug intolerance	24.85	14.11	3	8121	219101	50377899
Toxic nodular goitre	24.51	14.11	4	8120	16	50596984
Drug interaction	22.67	14.11	77	8047	199544	50397456
Eosinophilic pleural effusion	20.85	14.11	4	8120	46	50596954
Thyroid haemorrhage	20.19	14.11	4	8120	55	50596945
Acquired epidermolysis bullosa	20.13	14.11	4	8120	56	50596944
Toxic goitre	19.92	14.11	3	8121	6	50596994
Sopor	19.92	14.11	20	8104	19859	50577141
Thyroidectomy	19.70	14.11	7	8117	977	50596023
Electrocardiogram QT prolonged	19.43	14.11	32	8092	51854	50545146
Autoimmune neutropenia	19.29	14.11	4	8120	70	50596930
Functional residual capacity increased	19.13	14.11	4	8120	73	50596927
Insulin autoimmune syndrome	19.08	14.11	4	8120	74	50596926
Thyroid disorder	19.04	14.11	16	8108	12661	50584339
Hypoglycaemia	18.68	14.11	32	8092	53549	50543451
Stevens-Johnson syndrome	18.41	14.11	20	8104	21732	50575268
Respiratory syncytial virus infection	18.40	14.11	11	8113	5091	50591909
Jaundice cholestatic	18.38	14.11	11	8113	5100	50591900
Symptom masked	18.25	14.11	6	8118	663	50596337
Hypersensitivity vasculitis	18.07	14.11	10	8114	4005	50592995
Clinodactyly	18.05	14.11	4	8120	97	50596903
Thyroxine free abnormal	16.86	14.11	3	8121	22	50596978
Rheumatoid arthritis	16.42	14.11	6	8118	202544	50394456
Cardiac failure	16.27	14.11	37	8087	76003	50520997
Metabolic function test abnormal	16.05	14.11	4	8120	163	50596837
Microscopic polyangiitis	16.00	14.11	4	8120	165	50596835
Atrial fibrillation	15.98	14.11	44	8080	101701	50495299
Arthropathy	15.98	14.11	3	8121	157903	50439097
Spigelian hernia	15.60	14.11	3	8121	35	50596965
Kidney transplant rejection	15.44	14.11	9	8115	3978	50593022
Febrile neutropenia	15.11	14.11	42	8082	97625	50499375
Acute generalised exanthematous pustulosis	14.93	14.11	12	8112	8926	50588074
Mucosal erosion	14.42	14.11	6	8118	1281	50595719
Hepatitis cholestatic	14.19	14.11	10	8114	6107	50590893

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthyroidism	160.00	19.42	54	3568	8554	29562351
Agranulocytosis	76.53	19.42	41	3581	20299	29550606
Thyrotoxic periodic paralysis	66.56	19.42	11	3611	67	29570838
Hypothyroidism	54.09	19.42	30	3592	15876	29555029
Thyrotoxic crisis	49.81	19.42	11	3611	348	29570557
Kounis syndrome	48.32	19.42	15	3607	1814	29569091
Polymerase chain reaction	43.64	19.42	8	3614	95	29570810
Exomphalos	33.96	19.42	7	3615	158	29570747
Albumin urine present	33.38	19.42	8	3614	365	29570540
Cholestatic liver injury	32.88	19.42	11	3611	1686	29569219
Urine leukocyte esterase positive	32.72	19.42	8	3614	397	29570508
Goitre	30.39	19.42	10	3612	1457	29569448
Haemoglobinuria	29.75	19.42	8	3614	581	29570324
Mouth swelling	29.68	19.42	10	3612	1566	29569339
Pericarditis fungal	28.37	19.42	6	3616	154	29570751
Respiratory tract haemorrhage	25.86	19.42	8	3614	956	29569949
Autoimmune thyroiditis	25.29	19.42	8	3614	1028	29569877
Urine ketone body present	25.20	19.42	8	3614	1040	29569865
Axial spondyloarthritis	25.13	19.42	6	3616	269	29570636
Glycosuria	24.38	19.42	8	3614	1154	29569751
Loss of proprioception	23.30	19.42	6	3616	368	29570537
Tracheo-oesophageal fistula	22.47	19.42	6	3616	424	29570481
Blood cyanide increased	22.10	19.42	4	3618	44	29570861
Coagulation time shortened	21.17	19.42	5	3617	214	29570691
Blood sodium decreased	20.72	19.42	16	3606	14751	29556154
Electrolyte imbalance	19.83	19.42	14	3608	11260	29559645
Urinary bladder rupture	19.59	19.42	4	3618	86	29570819

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Agranulocytosis	357.87	13.38	158	10513	38071	64449990
Hyperthyroidism	282.27	13.38	108	10563	18071	64469990
Thyrotoxic crisis	252.95	13.38	54	10617	1062	64486999
Hypothyroidism	103.56	13.38	71	10600	40386	64447675
Antithyroid arthritis syndrome	66.06	13.38	9	10662	4	64488057
Thyrotoxic periodic paralysis	60.41	13.38	11	10660	90	64487971
Exophthalmos	50.30	13.38	16	10655	1544	64486517
Drug-induced liver injury	46.67	13.38	48	10623	47595	64440466
Goitre	44.66	13.38	20	10651	4953	64483108
Anti-neutrophil cytoplasmic antibody positive vasculitis	43.94	13.38	17	10654	2919	64485142
Polymerase chain reaction	39.31	13.38	8	10663	123	64487938
Kounis syndrome	36.51	13.38	15	10656	3010	64485051
Endocrine ophthalmopathy	30.06	13.38	8	10663	411	64487650
Polyarthritis	27.11	13.38	18	10653	9697	64478364
Albumin urine present	26.45	13.38	8	10663	653	64487408
Pericarditis fungal	25.97	13.38	6	10665	171	64487890
Blood thyroid stimulating hormone decreased	25.85	13.38	14	10657	5216	64482845
Haemoglobinuria	25.64	13.38	8	10663	725	64487336
Cardiac failure	25.55	13.38	63	10608	132310	64355751
Autoimmune thyroiditis	24.87	13.38	12	10659	3516	64484545
Neuroglycopenia	24.69	13.38	5	10666	75	64487986
Neutropenia	24.38	13.38	91	10580	239533	64248528
Toxic goitre	24.20	13.38	4	10667	17	64488044
Jaundice cholestatic	24.03	13.38	16	10655	8654	64479407
Cardiac arrest	23.32	13.38	67	10604	153997	64334064
Thyroxine free increased	22.40	13.38	8	10663	1099	64486962
Drug interaction	22.06	13.38	118	10553	361965	64126096
Cholestatic liver injury	21.45	13.38	11	10660	3668	64484393
Mucocutaneous candidiasis	21.24	13.38	4	10667	40	64488021
Electrocardiogram QT prolonged	21.15	13.38	43	10628	79405	64408656
Drug intolerance	21.12	13.38	3	10668	187989	64300072
Blood cyanide increased	20.90	13.38	4	10667	44	64488017
Atrial fibrillation	20.87	13.38	69	10602	171020	64317041
Respiratory tract haemorrhage	20.12	13.38	8	10663	1476	64486585
Urine leukocyte esterase positive	19.34	13.38	10	10661	3393	64484668
Hepatitis cholestatic	19.20	13.38	16	10655	12139	64475922
Sopor	19.02	13.38	24	10647	29637	64458424
Oropharyngeal pain	18.97	13.38	44	10627	88823	64399238
Functional residual capacity increased	18.81	13.38	4	10667	77	64487984
Thyroid haemorrhage	18.71	13.38	4	10667	79	64487982
Completed suicide	18.49	13.38	7	10664	224407	64263654
Acquired epidermolysis bullosa	18.39	13.38	4	10667	86	64487975
Urinary bladder rupture	18.05	13.38	4	10667	94	64487967
Pulmonary alveolar haemorrhage	17.89	13.38	14	10657	9724	64478337
Glycosuria	17.54	13.38	8	10663	2066	64485995
Thyroidectomy	16.92	13.38	6	10665	807	64487254
Coagulation time shortened	16.87	13.38	5	10666	381	64487680
Jaundice	16.30	13.38	29	10642	48483	64439578
Thyroid dermatopathy	16.22	13.38	3	10668	27	64488034
Immune-mediated hepatitis	16.15	13.38	8	10663	2481	64485580
Ventricular septal defect	15.91	13.38	5	10666	464	64487597
Mouth swelling	15.56	13.38	10	10661	5097	64482964
Metabolic function test abnormal	15.52	13.38	4	10667	181	64487880
Tri-iodothyronine increased	15.44	13.38	4	10667	185	64487876
Antineutrophil cytoplasmic antibody	15.43	13.38	3	10668	36	64488025
Hypersensitivity vasculitis	15.27	13.38	11	10660	6750	64481311
Toxic nodular goitre	15.21	13.38	3	10668	39	64488022
Bradycardia	14.69	13.38	48	10623	118171	64369890
Symptom masked	14.63	13.38	6	10665	1198	64486863
Respiratory syncytial virus infection	14.56	13.38	11	10660	7257	64480804
Tonsillitis	14.37	13.38	10	10661	5810	64482251
Cholestasis	14.03	13.38	26	10645	44846	64443215
Urine ketone body present	14.01	13.38	8	10663	3299	64484762
Eosinophilic pleural effusion	13.98	13.38	4	10667	269	64487792
Pure white cell aplasia	13.77	13.38	3	10668	65	64487996
Hepatitis	13.74	13.38	26	10645	45556	64442505
Hypoglycaemia	13.50	13.38	39	10632	89853	64398208
Oedema mucosal	13.44	13.38	6	10665	1473	64486588

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H03BB02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY ANTITHYROID PREPARATIONS Sulfur-containing imidazole derivatives
ATC	H03BB52	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY ANTITHYROID PREPARATIONS Sulfur-containing imidazole derivatives
MeSH PA	D013956	Antithyroid Agents
MeSH PA	D006727	Hormone Antagonists
FDA MoA	N0000175917	Thyroid Hormone Synthesis Inhibitors
FDA EPC	N0000175918	Thyroid Hormone Synthesis Inhibitor
CHEBI has role	CHEBI:50671	antithyroid drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperthyroidism	indication	34486009	DOID:7998
Thyrotoxic crisis	off-label use	29028009	DOID:12837
Agranulocytosis	contraindication	17182001	DOID:12987
Hypothyroidism	contraindication	40930008	DOID:1459
Factor II deficiency	contraindication	73975000
Leukopenia	contraindication	84828003	DOID:615
Pancytopenia	contraindication	127034005	DOID:12450
Liver function tests abnormal	contraindication	166603001
Drug-induced hepatitis	contraindication	235876009
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Bone marrow depression	contraindication	307762000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

Product	Applicant	Ingredients
Felimazole	Dechra, Ltd.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Thyroid peroxidase	Enzyme	P07202	PERT_HUMAN	INHIBITOR	IC50	5.57	WOMBAT-PK	CHEMBL
Lactoperoxidase	Enzyme	P22079	PERL_HUMAN		IC50	4.93	CHEMBL
Lactoperoxidase	Enzyme		PERL_BOVIN		IC50	5.08	CHEMBL
Dopamine beta-hydroxylase	Enzyme		DOPO_BOVIN		Ki	4.35	CHEMBL

External reference:

ID	Source
4017434	VUID
N0000145822	NUI
D00401	KEGG_DRUG
4017434	VANDF
C0025644	UMLSCUI
CHEBI:50673	CHEBI
MMZ	PDB_CHEM_ID
CHEMBL1515	ChEMBL_ID
DB00763	DRUGBANK_ID
6649	IUPHAR_LIGAND_ID
554Z48XN5E	UNII
1349907	PUBCHEM_CID
224936	RXNORM
2293	MMSL
31962	MMSL
5073	MMSL
d00290	MMSL
002139	NDDF
37656002	SNOMEDCT_US
404864000	SNOMEDCT_US
D008713	MESH_DESCRIPTOR_UI
4198	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0205	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0210	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	23155-070	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	23155-070	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	23155-071	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	23155-071	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	42254-008	TABLET	5 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	42254-009	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-640	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-640	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-641	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	49884-641	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2366	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3334	TABLET	5 mg	ORAL	ANDA	20 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	51293-820	TABLET	5 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	51293-821	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0850	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0949	TABLET	10 mg	ORAL	ANDA	18 sections
METHIMAZOLE	HUMAN PRESCRIPTION DRUG LABEL	1	53808-1044	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5135	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6071	TABLET	5 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60429-380	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60429-381	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60687-357	TABLET	5 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	60687-370	TABLET	10 mg	ORAL	ANDA	19 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	62135-205	TABLET	5 mg	ORAL	ANDA	12 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	62135-206	TABLET	10 mg	ORAL	ANDA	12 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2026	TABLET	5 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2027	TABLET	10 mg	ORAL	ANDA	18 sections
Methimazole	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2224	TABLET	10 mg	ORAL	ANDA	19 sections